|1.||He, Tongrong: 1 article (05/2012)|
|2.||Katusic, Zvonimir S: 1 article (05/2012)|
|3.||Saavedra, Joseph E: 1 article (02/2011)|
|4.||Weyerbrock, Astrid: 1 article (02/2011)|
|5.||Keefer, Larry K: 1 article (02/2011)|
|6.||Walbridge, Stuart: 1 article (02/2011)|
|7.||Oldfield, Edward H: 1 article (02/2011)|
|8.||Tomita, Shuhei: 1 article (01/2011)|
|9.||Hamano, Shuichi: 1 article (01/2011)|
|10.||Matsuda, Yuko: 1 article (01/2011)|
02/01/1998 - "Finally, pharmacological lowering of intracellular cGMP (using LY83583) resulted in decreased cAMP-stimulated Cl- secretion, and direct elevation of cGMP (using 8-bromo-cGMP or dibutyryl-cGMP) restored this hypoxia-induced activity. "
07/01/1992 - "Preincubation with LY 83583, an inhibitor of guanylate cyclase activation, abolished the initial hypoxia-elicited relaxation and subsequent contraction. "
10/01/1990 - "Chemiluminescence produced by LY 83583 was markedly potentiated by DETCA treatment, decreased at addition of exogenous SOD, and inhibited markedly by anoxia. "
05/01/1992 - "The inhibitor of guanylate cyclase activation, LY83583 (10 microM), increased tone under O2 atmosphere, eliminated the contraction to hypoxia, and inhibited the relaxation to reoxygenation, whereas indomethacin (10 microM) did not alter these responses. "
02/01/2008 - "Compared with cells cultured under normoxia, the hypoxia-preconditioned PBMNCs showed significantly lower reactive oxygen species (ROS) accumulation and higher cell survival under oxidative stress induced by LY-83583 (a superoxide generator). "
12/01/2002 - "Induction of the Cdk inhibitor p21 by LY83583 inhibits tumor cell proliferation in a p53-independent manner."
02/01/2011 - "This effect was achieved without significant changes in cerebral and tumor blood flow or arterial blood pressure, which indicates that the effect on vascular permeability is independent of changes in vascular tone induced by NO. This effect was mediated by activation of the NO/3',5'-cyclic guanosine monophosphate (cGMP) pathway, as it was blocked by guanylate cyclase inhibition by LY83583 and reproduced by the delivery of 8-bromoguanosine 5'-monophosphate or inhibition of cGMP degradation by the phosphodiesterase inhibitor zaprinast. "
02/01/1996 - "The BK-induced hyperalgesia was abolished by concomitant intradermal administration of either a guanylate cyclase inhibitor, methylene blue (10 nmol), or LY83583 (1 nmol). "
06/01/1999 - "The guanylate cyclase inhibitors LY 83583 (0.1-1.0 nmol) or ODQ (30-300 pmol) co-administered with glutamate, dose-dependently antagonised the glutamate-induced hyperalgesia. "
|4.||Amnesia (Dissociative Amnesia)
07/07/1997 - "Bilateral intrahippocampal administration of LY 83583 (2.5 micrograms per side) caused full amnesia for inhibitory avoidance when given immediately (0 min) after training, but not 30 min post-training. "
05/01/2010 - "Conversely, 8Br-cGMP overturned the amnesia induced by LY83583 but not that caused by KT-5823. "
05/01/2010 - "Intra-CA1 infusion of the beta-adrenergic receptor blocker timolol right after training hindered OR LTM and, although coadministration of noradrenaline reversed the amnesia caused by L-NN, LY83583, and KT5823, the amnesic effect of timolol was unaffected by coinfusion of 8Br-cGMP or SNAP, indicating that hippocampal beta-adrenergic receptors act downstream NO/sGC/PKG signaling. "
|1.||Guanylate Cyclase (Guanylyl Cyclase)
|3.||Methylene Blue (Methylthioninium Chloride)
|4.||NG-Nitroarginine Methyl Ester (L-NAME)
|9.||Nitric Oxide Synthase (NO Synthase)
|10.||5'-Guanylic Acid (GMP)